JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-cateninpathway is crucial for hair growth, and JW0061 activates this pathway effectively.
The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-cateninpathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
A user suggests that deeper microneedling with Verteporfin injections might help regrow hair in areas with scar tissue, alongside a DHT blocker. Another user explains that hair loss might be due to reduced Wnt/β-Catenin signaling and suggests that treatments like Minoxidil, Finasteride, and microneedling could potentially reverse it.
Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.
A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.